Cargando…

Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy

BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics...

Descripción completa

Detalles Bibliográficos
Autores principales: Menkiszak, Janusz, Chudecka-Głaz, Anita, Cymbaluk-Płoska, Aneta, Celewicz, Aleksander, Kojs, Zbigniew, Szajda, Mariusz, Świniarska, Maria, Bedner, Ryszard, Jurczak, Anna, Celewicz, Marta, Cieszyńska, Monika, Lubiński, Jan, Gronwald, Jacek
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419350/
https://www.ncbi.nlm.nih.gov/pubmed/30918533
http://dx.doi.org/10.1186/s13053-019-0109-5
_version_ 1783403924682702848
author Menkiszak, Janusz
Chudecka-Głaz, Anita
Cymbaluk-Płoska, Aneta
Celewicz, Aleksander
Kojs, Zbigniew
Szajda, Mariusz
Świniarska, Maria
Bedner, Ryszard
Jurczak, Anna
Celewicz, Marta
Cieszyńska, Monika
Lubiński, Jan
Gronwald, Jacek
author_facet Menkiszak, Janusz
Chudecka-Głaz, Anita
Cymbaluk-Płoska, Aneta
Celewicz, Aleksander
Kojs, Zbigniew
Szajda, Mariusz
Świniarska, Maria
Bedner, Ryszard
Jurczak, Anna
Celewicz, Marta
Cieszyńska, Monika
Lubiński, Jan
Gronwald, Jacek
author_sort Menkiszak, Janusz
collection PubMed
description BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics of these neoplasms are not well known. In this study, we determined the selected parameters such as age at cancer diagnosis, time from RRSO to the diagnosis of cancer, and significance of BRCA1 mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up. METHODS: The material comprised of 195 BRCA1 carriers who performed RRSO between years 1999–2012. In this period, 16 patients developed cancer (6-primary breast cancer, 3-contralateral breast cancer, 5-relapse of breast cancer, 2-peritoneal cancer). They were subject of the further analysis. RESULTS: During the follow-up period mean age of patients after RRSO at the time of cancer diagnosis was 53.19. The mean age of patients diagnosed with primary breast cancer was 50, contralateral breast cancer – 58.67, recurrence of breast cancer - 51 and peritoneal cancer 60. The mean time periods from RRSO to the diagnosis of primary, contralateral, recurrence breast cancer were 53, 58.67 and 25,4 months respectively and of peritoneal cancer 46 months. BRCA1 c.5266dupC mutation carriers demonstrated significantly shorter time of cancer development compared to patients carrying c.181T > G and c.4035delA mutations. Peritoneal cancer was only observed in two c.181T > G BRCA1 mutation carriers. CONCLUSIONS: The mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupC BRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively.
format Online
Article
Text
id pubmed-6419350
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-64193502019-03-27 Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy Menkiszak, Janusz Chudecka-Głaz, Anita Cymbaluk-Płoska, Aneta Celewicz, Aleksander Kojs, Zbigniew Szajda, Mariusz Świniarska, Maria Bedner, Ryszard Jurczak, Anna Celewicz, Marta Cieszyńska, Monika Lubiński, Jan Gronwald, Jacek Hered Cancer Clin Pract Research BACKGROUND: Since more than two decades Risk-reducing salpingo-oophorectomy (RRSO) is recommended and widely accepted by BRCA1/2 carriers as a method reducing ovarian cancer risk and improving survival rate. After RRSO, there remains a risk of breast cancer and peritoneal cancer. The characteristics of these neoplasms are not well known. In this study, we determined the selected parameters such as age at cancer diagnosis, time from RRSO to the diagnosis of cancer, and significance of BRCA1 mutation type in patients diagnosed with breast or peritoneal cancer during postoperative follow-up. METHODS: The material comprised of 195 BRCA1 carriers who performed RRSO between years 1999–2012. In this period, 16 patients developed cancer (6-primary breast cancer, 3-contralateral breast cancer, 5-relapse of breast cancer, 2-peritoneal cancer). They were subject of the further analysis. RESULTS: During the follow-up period mean age of patients after RRSO at the time of cancer diagnosis was 53.19. The mean age of patients diagnosed with primary breast cancer was 50, contralateral breast cancer – 58.67, recurrence of breast cancer - 51 and peritoneal cancer 60. The mean time periods from RRSO to the diagnosis of primary, contralateral, recurrence breast cancer were 53, 58.67 and 25,4 months respectively and of peritoneal cancer 46 months. BRCA1 c.5266dupC mutation carriers demonstrated significantly shorter time of cancer development compared to patients carrying c.181T > G and c.4035delA mutations. Peritoneal cancer was only observed in two c.181T > G BRCA1 mutation carriers. CONCLUSIONS: The mean age of cancer diagnosis and the mean time periods from RRSO to the diagnosis of cancer are similar to those observed by other researchers. The carriers of c.181T > G and c.5266dupC BRCA1 mutation should be the subject further studies in context of breast and peritoneal cancer risk or time of cancer development after RRSO, respectively. BioMed Central 2019-03-14 /pmc/articles/PMC6419350/ /pubmed/30918533 http://dx.doi.org/10.1186/s13053-019-0109-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Menkiszak, Janusz
Chudecka-Głaz, Anita
Cymbaluk-Płoska, Aneta
Celewicz, Aleksander
Kojs, Zbigniew
Szajda, Mariusz
Świniarska, Maria
Bedner, Ryszard
Jurczak, Anna
Celewicz, Marta
Cieszyńska, Monika
Lubiński, Jan
Gronwald, Jacek
Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title_full Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title_fullStr Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title_full_unstemmed Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title_short Selected features of breast and peritoneal cancers diagnosed in BRCA1 carriers after risk-reducing salpingo-oophorectomy
title_sort selected features of breast and peritoneal cancers diagnosed in brca1 carriers after risk-reducing salpingo-oophorectomy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6419350/
https://www.ncbi.nlm.nih.gov/pubmed/30918533
http://dx.doi.org/10.1186/s13053-019-0109-5
work_keys_str_mv AT menkiszakjanusz selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT chudeckagłazanita selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT cymbalukpłoskaaneta selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT celewiczaleksander selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT kojszbigniew selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT szajdamariusz selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT swiniarskamaria selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT bednerryszard selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT jurczakanna selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT celewiczmarta selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT cieszynskamonika selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT lubinskijan selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy
AT gronwaldjacek selectedfeaturesofbreastandperitonealcancersdiagnosedinbrca1carriersafterriskreducingsalpingooophorectomy